Fig. 3From: The impact of immunosuppressive therapy on secondary infections and antimicrobial use in COVID-19 inpatients: a retrospective cohort studyAntimicrobial use in Days of Therapy (DOT) per 1000 patient-days, stratified by antimicrobial class and presence or absence of a microbiologically confirmed infectionBack to article page